Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease

导出原文传递

翻译打印收藏纠错

作者： Sandborn,W.J. ^[1] ; Colombel,J.-F. ^[2] ; D'Haens,G. ^[3] ; Plevy,S.E. ^[4] ; Panés,J. ^[5] ; Robinson,A.M. ^[6] ; Pollack,P.F. ; Zhou,Q. ; Castillo,M. ; Thakkar,R.B.

作者单位： Hepatogastroenterology, Centre Hospitalier Universitaire de Lille, Lille, France ^[1] AbbVie Inc., North Chicago, IL, United States ^[2] Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine ^[3] Academic Medical Center, Amsterdam, Netherlands and Imelda GI Clinical Research Center, Bonheiden ^[4] Hospital Clínic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain ^[5] UCSD Inflammatory Bowel Disease Center, Division of Gastroenterology, UC San Diego Health System ^[6]

关键词 Adalimumab C-reactive protein Clinical remission Crohn's disease Dose

发布时间 2014-02-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交